Safety Assessment of Niacin in the U.S. Food and Drug Administration's Mini-Sentinel System

    Basic Details
    Date
    Monday, November 6, 2017
    Type
    Publication
    Medical Product
    extended-release (ER) niacin
    fenofibrate
    Health Outcome(s)
    gastrointestinal (GI) bleed
    intracranial hemorrhage
    Description

    The authors of this report compared rates of major gastrointestinal bleeding and intracranial hemorrhage among initiators of extended-release niacin and initiators of fenofibrate.

    Author(s)

    Joshua J. Gagne PharmD, ScD; Monika Houstoun PharmD; Marsha E. Reichman PhD; Christian Hampp PhD; James H. Marshall MPH; Sengwee Toh ScD

    Corresponding Author

    J. J. Gagne, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA. Email: jgagne@bwh.harvard.edu